Skip to main content

JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 8, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Feb. 8, 2024 -- For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study published in the Feb. 8 issue of the New England Journal of Medicine.

Robert Bissonnette, M.D., from Innovaderm Research in Montreal, and colleagues conducted a phase 2 dose-finding trial involving 255 patients with moderate-to-severe plaque psoriasis who were randomly assigned to receive JNJ-77242113 at a dose of 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, or 100 mg twice daily or placebo for 16 weeks. A reduction from baseline of at least 75 percent in the Psoriasis Area and Severity Index (PASI) score (PASI 75 response) at week 16 was the primary end point.

The researchers found that the percentage of patients with a PASI 75 response was higher among those receiving JNJ-77242113 versus placebo (37, 51, 58, 65, and 79 percent in the 25-mg once-daily, 25-mg twice-daily, 50-mg once-daily, 100-mg once-daily, and 100-mg twice-daily groups, respectively, versus 9 percent), with a significant dose-response relationship observed. COVID-19 and nasopharyngitis were the most common adverse events. The percentages of patients with at least one adverse event was similar in the combined JNJ-77242113 dose group and the placebo group (52 and 51 percent, respectively).

"In this phase 2 trial, JNJ-77242113, an oral interleukin-23-receptor antagonist peptide, showed a dose-response relationship and greater efficacy than placebo," the authors write.

The study was funded by Janssen Research and Development, which is developing JNJ-77242113.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

Coexistence of Psoriatic Arthritis, Atopic Dermatitis May Offer Treatment Insights

MONDAY, May 13, 2024 -- Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to...

Tobacco Smoking Reduces the Odds of Psoriasis Improvement

WEDNESDAY, April 24, 2024 -- Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced...

AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis

FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.